Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ETN101 in Advanced Hepatocellular Carcinoma
NCT06326502Phase 1Recruiting
- Sponsor
- Etnova Therapeutics
- Start
- Feb 2024
- Primary completion
- Mar 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ETN101 in hepatocellular carcinoma (HCC), sponsored by Etnova Therapeutics. Primary endpoint: Dose-limiting Toxicity at 3 weeks. Started Feb 2024; status: recruiting.
02
Drugs
ETN101
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT06326502.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06326502.